IPSC-CMs Combined with LVAD or CABG for the Treatment of Heart Failure

Inclusion Criteria: * Male or female aged 35-75 years (inclusive) at the time of signing the informed consent form. * Capable of understanding the informed consent form, voluntarily agreeing to participate in the trial, and signing the informed consent form. * Diagnosed with end-stage heart failure. * Receiving optimized medical therapy for heart failure, with New York Heart Association (NYHA) functional class III-IV. * Echocardiography demonstrating regional hypokinesia or akinesia of the ventricular wall. * Cardiac magnetic resonance imaging (MRI) confirming left ventricular ejection fraction (LVEF) ≤35%. * Myocardial perfusion-metabolism imaging with radionuclide indicating infarcted myocardium in the left anterior descending (LAD) artery territory. * Meets criteria for coronary artery bypass grafting (CABG) under cardiopulmonary bypass during screening and requires CABG surgery. * For patients enrolled in the LVAD implantation group, the following additional criteria must be met: 1. Definitive indication for LVAD implantation due to end-stage heart failure. 2. Anticipated significant improvement in hemodynamic stability post-LVAD implantation, with potential for further cardiac functional improvement via myocardial cell injection. 3. Absence of significant contraindications for LVAD surgery. Exclusion Criteria: * History of pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT). * Severe valvular heart disease. * Acute myocardial infarction or history of percutaneous coronary intervention (PCI) within 1 month prior to screening. * Non-ischemic cardiomyopathy or acute viral myocarditis. * Acute cerebrovascular event within 1 month prior to screening. * History of malignancy within 5 years prior to screening. * Autoimmune disease or chronic use of immunosuppressive agents. * History of organ transplantation. * Planned concurrent major surgery (excluding left ventricular aneurysm resection or left atrial appendage closure/resection). * Malignant ventricular arrhythmia. * Contraindications for CABG surgery. * Positive serology for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody. * Inability to undergo cardiac MRI or PET/CT imaging. * Contraindications to immunosuppressive therapy or inability to comply with the protocol-specified immunosuppressive regimen. * Hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, tacrolimus, macrolides, prednisone acetate/methylprednisolone, other corticosteroids, or basiliximab. * Participation in another clinical trial within 3 months prior to screening. * Pregnancy, lactation, or positive pregnancy test in female patients. * Any other condition deemed by the investigator to render the patient unsuitable for trial participation.